Obiltoxaximab

[1]Nagy CF, et al. Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule. Clin Transl Sci. 2017 Jan;10 (1) :12-19.|[2]Yamamoto BJ, et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrob Agents Chemother. 2016 Sep 23;60 (10) :5796-805.|[3]Hou A W, et al. Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection[J]. Annals of Pharmacotherapy, 2017, 51 (10) : 908-913.|[4]Yamamoto B J, et al. Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre-and postexposure prophylaxis in animal models of inhalational anthrax[J]. Antimicrobial agents and chemotherapy, 2016, 60 (10) : 5796-5805.|[5]Biron B, et al. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax[J]. Antimicrob Agents Chemother. 2015 Apr;59 (4) :2206-14.